PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
$1.25
+4.62%
$369.6M
No data for this timeframe.
Vol
Market Cap$369.6M
Cap SizeSmall Cap
Analyst ConsensusBuy (56%)
Inst. Holders8 funds
Inst. Value$57.7M
Inst. Activity6 buys / 0 sells
Insider Activity0B / 3S
Insider Net $-$149.6K
Reddit Sentiment33° Cool
SEC Reports4
Press Releases1
Recent Activity
May 20, 2026
short_volume
Short Volume: PACB — 62.1% short (1.2M / 1.9M)
Short: 1,151,511 | Exempt: 7,942 | TRF Vol: 1,855,087 | Short Ratio: 62.1% | Off-exchange volume (da
Apr 21, 2026
Press
PacBio announced that Lucid Genomics has joined its PacBio Compatible partner program, integrating its cloud-native bioi
Impact 3/10
Apr 16, 2026
SEC
PacBio announced a date for its Q1 2026 earnings call but did not release financial results or provide updated guidance.
PRESS-RELEASE — Impact 3/10
Apr 8, 2026
Insider
Gibson Christopher sold 57,473 shares
Director @ $0.00 ($0.00)
Apr 8, 2026
Insider
Gibson Christopher sold 77,842 shares
Director @ $0.00 ($0.00)
Apr 1, 2026
Insider
Gibson James R II sold 88,185 shares
See Remarks @ $1.37 ($120.8K)
Mar 5, 2026
SEC
A cluster of insider transactions at Pacific Biosciences of California (PACB) over the past week consists primarily of n
CLUSTER — Impact 3/10
Mar 5, 2026
SEC
Pacific Biosciences appointed Christopher Gibson, Ph.D., to its Board of Directors and Science and Technology Committee,
8-K — Impact 3/10
Price Targets
$2.46
+97.5% upside
Strong Buy
Current $1.25
Low $1.50
Median $2.63
High $3.00
6 analysts
$1.50
$3.00
Analyst Ratings
4Strong Buy
5Buy
6Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| Apr 14, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| Mar 6, 2026 | Barclays | DOWNGRADE | Equal-Weight → Underweight |
| Dec 15, 2025 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.13 ▼ -0.6% | $-0.14 — $-0.12 | 3% YoY | 6 |
| Next Q | $-0.13 ▼ -2.0% | $-0.13 — $-0.12 | -4% YoY | 6 |
| Current FY | $-0.50 ▲ +0.7% | $-0.52 — $-0.49 | 5% YoY | 6 |
| Next FY | $-0.40 ▲ +3.4% | $-0.48 — $-0.23 | 20% YoY | 6 |
Latest Reports
NEUTRAL
Press
3/10
PacBio announced that Lucid Genomics has joined its PacBio Compatible partner program, integrating its cloud-native bioi
Apr 21, 2026
NEUTRAL
PRESS-RELEASE
3/10
PacBio announced a date for its Q1 2026 earnings call but did not release financial results or provide updated guidance.
Apr 16, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Pacific Biosciences of California (PACB) over the past week consists primarily of n
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $31.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $7.2M | NEW |
| TWO SIGMA INVESTMENTS, LP | $5.4M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $4.6M | NEW |
| MORGAN STANLEY | $4.5M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 8, 2026 | Gibson Christopher | A | $0.00 |
| Apr 8, 2026 | Gibson Christopher | A | $0.00 |
| Apr 1, 2026 | Gibson James | SELL | $120.8K |
| Mar 3, 2026 | Van Oene | SELL | $9.8K |
| Mar 3, 2026 | Gibson Christopher | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
8 institutional holders with $57.7M total value (30,840,174 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 17,037,314 | $31.9M | 55.2% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 3,850,600 | $7.2M | 12.5% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 2,877,184 | $5.4M | 9.3% | DOUBLED +616.1% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,465,853 | $4.6M | 8.0% | NEW |
| 5 | MORGAN STANLEY | 2,410,540 | $4.5M | 7.8% | DOUBLED +434.2% |
| 6 | BANK OF AMERICA CORP /DE/ | 1,854,814 | $3.5M | 6.0% | ADD +25.9% |
| 7 | WELLS FARGO & COMPANY/MN | 314,014 | $587.2K | 1.0% | ADD +35.4% |
| 8 | FMR LLC | 29,855 | $55.8K | 0.1% | ADD +60.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 3,850,600 | — | $7.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 401,766 | 2,877,184 | +616.1% | $5.4M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 451,215 | 2,410,540 | +434.2% | $4.5M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,472,690 | 1,854,814 | +25.9% | $3.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 231,955 | 314,014 | +35.4% | $587.2K | 2025-Q4 |
| FMR LLC | ADD | 18,576 | 29,855 | +60.7% | $55.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 702,703 | 1,472,690 | +109.6% | $1.9M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 831,770 | 451,215 | -45.8% | $577.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 401,766 | — | $514.3K | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 3,371,732 | 831,770 | -75.3% | $1.0M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,197,055 | 702,703 | -41.3% | $871.4K | 2025-Q2 |
| FMR LLC | DOUBLED | 8,746 | 19,123 | +118.6% | $23.7K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 542,200 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 5,651,558 | 3,371,732 | -40.3% | $4.0M | 2025-Q1 |
| UBS Group AG | ADD | 1,486,015 | 2,284,278 | +53.7% | $2.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,113,577 | 542,200 | -51.3% | $639.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 909,581 | 308,622 | -66.1% | $364.2K | 2025-Q1 |
| FMR LLC | TRIM | 22,653 | 8,746 | -61.4% | $10.3K | 2025-Q1 |
| MORGAN STANLEY | ADD | 3,892,542 | 5,651,558 | +45.2% | $10.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 642,849 | 1,486,015 | +131.2% | $2.7M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 328,622 | 909,581 | +176.8% | $1.7M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 129,221 | 163,154 | +26.3% | $298.6K | 2024-Q4 |
| MORGAN STANLEY | ADD | 3,079,756 | 3,892,542 | +26.4% | $6.6M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,040,303 | — | $3.5M | 2024-Q3 |
5 unique insiders with 3 transactions. Net insider value: -$149.6K ($0.00 bought, $149.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 8, 2026 | Gibson Christopher | Director | A | 57,473 | $0.00 | $0.00 |
| Apr 8, 2026 | Gibson Christopher | Director | A | 77,842 | $0.00 | $0.00 |
| Apr 1, 2026 | Gibson James R II | See Remarks | SELL | 88,185 | $1.37 | $120.8K |
| Mar 3, 2026 | Van Oene Mark | See Remarks | SELL | 6,504 | $1.51 | $9.8K |
| Mar 3, 2026 | Gibson Christopher | Director | A | 53,913 | $0.00 | $0.00 |
| Mar 3, 2026 | HENRY CHRISTIAN O | See Remarks | SELL | 12,497 | $1.51 | $18.9K |
| Mar 3, 2026 | Gibson Christopher | Director | A | 73,087 | $0.00 | $0.00 |
| Feb 27, 2026 | Gibson James R II | See Remarks | A | 333,848 | $0.00 | $0.00 |
| Feb 27, 2026 | Van Oene Mark | See Remarks | A | 500,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Farmer Michele | See Remarks | A | 89,835 | $0.00 | $0.00 |
| Feb 27, 2026 | Gibson James R II | See Remarks | A | 667,696 | $0.00 | $0.00 |
| Feb 27, 2026 | Van Oene Mark | See Remarks | A | 1,000,000 | $0.00 | $0.00 |
| Feb 27, 2026 | HENRY CHRISTIAN O | See Remarks | A | 920,810 | $0.00 | $0.00 |
| Feb 27, 2026 | HENRY CHRISTIAN O | See Remarks | A | 1,841,621 | $0.00 | $0.00 |
| Feb 27, 2026 | Farmer Michele | See Remarks | A | 179,670 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
PRESS-RELEASE
3/10
PacBio announced a date for its Q1 2026 earnings call but did not release financial results or provi
Apr 16, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Pacific Biosciences of California (PACB) over the past week con
Mar 5, 2026
NEUTRAL
8-K
3/10
Pacific Biosciences appointed Christopher Gibson, Ph.D., to its Board of Directors and Science and T
Mar 5, 2026
BULLISH
INST-CLUSTER
7/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
Current analyst consensus: Hold (56% buy). Based on 16 analysts: 4 strong buy, 5 buy, 6 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$2.46 mean target
+97.5% upside
Strong Buy (2.13)
$1.50 Low
$3.00 High
| Metric | Value |
|---|---|
| Current Price | $1.25 |
| Target Low | $1.50 |
| Target Mean | $2.46 |
| Target Median | $2.63 |
| Target High | $3.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (2.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.13 | $-0.14 | $-0.12 | 3.3% | -0.6% | 2↑ 1↓ | $0.0B | 2.1% | 6 |
| Next Q 2026-09-30 |
$-0.13 | $-0.13 | $-0.12 | -4.4% | -2.0% | 1↑ 2↓ | $0.0B | 13.2% | 6 |
| Current FY 2026-12-31 |
$-0.50 | $-0.52 | $-0.49 | 5.1% | +0.7% | 2↑ 1↓ | $0.2B | 5.2% | 6 |
| Next FY 2027-12-31 |
$-0.40 | $-0.48 | $-0.23 | 20.0% | +3.4% | 3↑ 1↓ | $0.2B | 14.4% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.126 | |
| 7d ago | $-0.125 | -0.001 |
| 30d ago | $-0.125 | -0.001 |
| 60d ago | $-0.125 | -0.000 |
| 90d ago | $-0.128 | +0.002 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Apr 14, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Mar 6, 2026 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Dec 15, 2025 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 5 | 6 | 1 | 0 | 56% | |
| Apr 1, 2026 | 4 | 5 | 6 | 1 | 0 | 56% | |
| Mar 1, 2026 | 4 | 5 | 7 | 0 | 0 | 56% | |
| Feb 1, 2026 | 3 | 5 | 7 | 0 | 0 | 53% | |
| Jan 1, 2026 | 4 | 5 | 7 | 0 | 0 | 56% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 21, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
May 20, 2026
short_volume
Short Volume: PACB — 62.1% short (1.2M / 1.9M)
Short: 1,151,511 | Exempt: 7,942 | TRF Vol: 1,855,087 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: PACB — 62.6% short (1.6M / 2.6M)
Short: 1,646,969 | Exempt: 9,202 | TRF Vol: 2,630,200 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: PACB — 72.6% short (3.7M / 5.2M)
Short: 3,743,098 | Exempt: 31,270 | TRF Vol: 5,155,038 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: PACB — 70.6% short (3.6M / 5.2M)
Short: 3,642,036 | Exempt: 13,251 | TRF Vol: 5,155,118 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: PACB — 57.1% short (2.2M / 3.9M)
Short: 2,234,719 | Exempt: 10,325 | TRF Vol: 3,915,802 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
fda
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking
May 8, 2026
short_volume
Short Volume: PACB — 58.8% short (2.7M / 4.7M)
Short: 2,736,771 | Exempt: 118,871 | TRF Vol: 4,654,854 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
PACB Q1 2026 Earnings After Market Close — 2026-05-07
Apr 29, 2026
short_volume
Short Volume: PACB — 65.6% short (2.1M / 3.2M)
Short: 2,121,912 | Exempt: 29,067 | TRF Vol: 3,234,556 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: PACB — 64.3% short (1.3M / 2.0M)
Short: 1,254,273 | Exempt: 13,351 | TRF Vol: 1,950,134 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: PACB — 66.1% short (2.2M / 3.3M)
Short: 2,162,313 | Exempt: 8,277 | TRF Vol: 3,269,560 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: PACB — 67.7% short (1.7M / 2.6M)
Short: 1,738,703 | Exempt: 1,521 | TRF Vol: 2,568,047 | Short Ratio: 67.7% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: PACB — 63.3% short (1.0M / 1.7M)
Short: 1,049,221 | Exempt: 2,588 | TRF Vol: 1,656,529 | Short Ratio: 63.3% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
contract
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem <pre>Expands access to streamlined genomic data analysis acros
Apr 21, 2026
short_volume
Short Volume: PACB — 59.1% short (1.8M / 3.1M)
Short: 1,846,201 | Exempt: 2,878 | TRF Vol: 3,125,309 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)